TRUXIMA

(Truxima)

Phase 3Biologic

TRUXIMA is one of 40 biologic programs targeting Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

FDA Application

NDA/BLA/ANDA regulatory filings

Pipeline

Status by Indication[3][1]

Indication

Chronic Lymphocytic Leukemia/small Lymphocytic LymphomaActive, not recruiting

Chronic Lymphocytic Leukemia/small Lymphocytic LymphomaPhase 3

Active, not recruiting

Competition

Competitive Landscape

42 competitors in Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma

#DrugCompanyPhaseTrials

Zydelig

Jaypirca

6 3

Rituxan

Roche

Phase 3

6 4

Cytoxan

BBaxter Healthcare Corporation

Phase 3

2 5

Treanda

AAzurity Pharmaceuticals

Phase 3

2 6

Nemtabrutinib

Merck & Co.

Phase 3

3 7

Venclexta

AbbVie

Phase 2

7 8

Gazyva

Roche

Phase 2

5 9

Beqalzi

Fludara

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2031

Phase 3Active, not recruiting

Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma

NCT05624554

Clinical

Trials by Indication[1]

Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma1 trial

A Study of Nemtabrutinib vs Chemoimmunotherapy for Participants With Previously Untreated Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Without TP53 Aberrations (MK-1026-008, BELLWAVE-008)

Active, not recruiting· Merck & Co. logo

Merck & Co.·Phase 3·NCT05624554·300 enrolled

Regulatory

FDA Approval Timeline[4]

Nov 28, 2018

TRUXIMA

BLA BLA761088

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for Truxima. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — Truxima compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for Truxima. EMBL-EBI & Wellcome Sanger Institute.
[4]
OpenFDA — FDA approval records (BLA BLA761088). U.S. Food & Drug Administration.
[5]
SEC EDGAR — Cephalon company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Biologic[2]
Highest Phase: Phase 3[1]
Company: CCephalon

TRUXIMA

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2031

Trials by Indication[1]

Chronic Lymphocytic Leukemia/small Lymphocytic Lymphoma1 trial

FDA Approval Timeline[4]

References

Drug Info

Quick Facts

Related News